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Evidence-Based Medicine (EBM) is a
methodological and systematic approach,
which is considered as the most robust
form of the empirical medicine as it sorts
evidence according to their credibility. It
is widely used in clinical decision-making
and has several advantages, including:
(1) provision of a very well-founded
and objective method to adhere to high
quality and safety standards in medi-
cal practice, (2) facilitation of translation
of clinical research findings into clini-
cal practice, and (3) significant reduction
of health care costs. EBM can be sum-
marized into five practical steps include
searching for an answer to a clinical
question, searching for the evidence, crit-
ically appraising and reviewing the exist-
ing evidence, combining credible evidence
with clinical experience and the patients’
viewpoints, and finally, evaluating the
process.
As it is widely believed that evidence
is not properly classified and there is
no credible assessment method in data
on biomedical literatures, it could be
suggested that EBM is of limited use
in this branch of science (Clancy and
Cronin, 2005). Therefore, in biomedicine,
although there are literature redundan-
cies and large number of evidences, they
are only useful if a systematic searching
approach is taken. Moreover, a structured
process needs to be in place to ana-
lyze the findings and critically appraise
them.
Due to the existence of overwhelm-
ingly disorganized data in the field of
biomedicine that lead to non-categorized
and non-screened information, it could
be suggested that there is a need
for development of a novel method-
ology considering different levels of
evidence (Ioannidis, 2005; Cho, 2007).
Moreover, the hierarchy of EBM in
biomedicine is questionable; the need
is more highlighted (Mantzoukas,
2008).
Evidence Based Bio-Medicine (EBBM)
can be considered as a novel method
in biomedical literatures. This technique
focuses on the evaluation and ranking
of different articles with widely available
techniques in the field based on their cred-
ibility, limitations, and biases. The aim of
this letter is to analyze the effectiveness of
EBBM in order to shed some light on its
limitations. It could lead to classification of
evidence on biomedical science issues and
facilitate their practical application with
the view of addressing the raised issue in
this letter.
In order to present the case more
clearly, the following examples are
used:
1. Various studies have been carried out
in order to shed some light on the
genetic susceptibility to thyroid can-
cer using molecular diagnostic and
predictive biomarker (Ruggeri et al.,
2008; Nikiforova and Nikiforov, 2009;
Landa and Robledo, 2011). The meth-
ods and techniques used in differ-
ent studies may vary. Sample size and
selection methods, using fresh tissue
samples or paraffin embedded blocks
and especially, the details of tech-
niques used in different studies can
differ. This can raise the question
as to whether there exists a method
of classification, way of evaluation,
assessment of scientific credibility, and
ultimately, a ranking of the level of
evidence on their validity. Moreover,
it should be clarified that how other
researchers interested in complemen-
tary studies on the same subject can
conduct their study and select the
most valid studies based on what
criteria?
2. There is enormous number of meta-
analyses of genome-wide association
studies (GWAS) that aimed to detect
genetic variants with gradually smaller
effects, but force to publish the out-
comes of the studies of new genetic
associations has narrowed the time
available for watchful consideration of
all of their methodological aspects. A
survey of the literature from 2007 to
2010, to offer empirical evidence on
the methods used in meta-analyses of
GWAS, showed that a great variety
of methods are being used, but the
logic of their selection is often unclear
(Gögele et al., 2012). This review also
highlighted how important method-
ological features have achieved unsat-
isfactory attention, potentially leading
to missed opportunities for improv-
ing gene discovery and characteriza-
tion. Evaluation of power to repli-
cate findings was inadequate, and the
number of variants selected for replica-
tion was not associated with replication
sample size. Additional methodolog-
ical efforts and clear guidance are
required to offer the optimal meth-
ods or trade-offs between alternative
methods.
Finally, it could be suggested that differ-
ent levels of evidence should be based on:
(1) the study types such as in vitro, in vivo,
and clinical trial (2) laboratory techniques
used (3) “omics” approach to the hypoth-
esis testing like genomics, proteomics,
and (4) Utilize a checklist to classify
and grade the evidence in biomedicine.
Moreover, further investigation and testing
of the validity of these tools is needed,
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which indicate that the EBBM scales
are valid and reliable instruments for
measuring biomedical datas’ confidence in
the process and the outcomes basing on
the evidence.
Hopefully, this may encourage sci-
entists in the field of biomedicine,
molecular epidemiology, bioinformat-
ics, and translational medicine to
contribute in the foundation of a
novel and functional methodological
approach using different levels of evidence
raised above.
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